S T Kim1, I-G Do, J Lee, I Sohn, K-M Kim, W K Kang. 1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea.
Abstract
INTRODUCTION: Molecular targets are emerging rapidly and the development of clinical tests that simultaneously screen for multiple targets has become especially important. We assessed the gene expression levels of three known targets in advanced gastric cancer, epidermal growth factor receptor (EGFR), human epidermal growth factor 2 (HER2), and N-methyl-N-nitrosoguanidine human osteosarcoma transforming gene (MET), using the nCounter® assay (NanoString Technologies, Seattle, WA, USA) and compared these results with protein overexpression, detected by immunohistochemistry, to evaluate the performance of this new technology. METHODS: We investigated 42 formalin-fixed, paraffin-embedded tumor samples from patients with gastric cancer. A NanoString-based assay containing a 522 kinase gene panel was investigated. We analyzed the correlations between immunohistochemical findings and kinase gene expression levels of EGFR, HER2 and MET to validate this assay. RESULTS: EGFR, HER2, and MET overexpression were observed in 7 (16.6 %), 5 (11.9 %), and 3 (7.1 %) cases, respectively. For EGFR, HER2, and MET, the concordance rates between the NanoString-based assay results and the immunohistochemistry methods were 83.3, 97.6, and 100 %, respectively. Relative to immunohistochemistry findings, the NanoString-based assay sensitivities and specificities were 85.7 and 82.8 % for EGFR, 100 and 97.2 % for HER2, and 100 and 100 % for MET, respectively. CONCLUSIONS: We found a high concordance between immunohistochemistry- and nCounter-based assessments of EGFR, HER2, and MET in advanced gastric cancer. Judged against immunohistochemistry results, the NanoString assay had high sensitivities and high specificities. These results suggest that the nCounter assay provides a reliable, high-throughput assay to simultaneously screen for the overexpression of several target proteins.
INTRODUCTION: Molecular targets are emerging rapidly and the development of clinical tests that simultaneously screen for multiple targets has become especially important. We assessed the gene expression levels of three known targets in advanced gastric cancer, epidermal growth factor receptor (EGFR), human epidermal growth factor 2 (HER2), and N-methyl-N-nitrosoguanidinehumanosteosarcoma transforming gene (MET), using the nCounter® assay (NanoString Technologies, Seattle, WA, USA) and compared these results with protein overexpression, detected by immunohistochemistry, to evaluate the performance of this new technology. METHODS: We investigated 42 formalin-fixed, paraffin-embedded tumor samples from patients with gastric cancer. A NanoString-based assay containing a 522 kinase gene panel was investigated. We analyzed the correlations between immunohistochemical findings and kinase gene expression levels of EGFR, HER2 and MET to validate this assay. RESULTS:EGFR, HER2, and MET overexpression were observed in 7 (16.6 %), 5 (11.9 %), and 3 (7.1 %) cases, respectively. For EGFR, HER2, and MET, the concordance rates between the NanoString-based assay results and the immunohistochemistry methods were 83.3, 97.6, and 100 %, respectively. Relative to immunohistochemistry findings, the NanoString-based assay sensitivities and specificities were 85.7 and 82.8 % for EGFR, 100 and 97.2 % for HER2, and 100 and 100 % for MET, respectively. CONCLUSIONS: We found a high concordance between immunohistochemistry- and nCounter-based assessments of EGFR, HER2, and MET in advanced gastric cancer. Judged against immunohistochemistry results, the NanoString assay had high sensitivities and high specificities. These results suggest that the nCounter assay provides a reliable, high-throughput assay to simultaneously screen for the overexpression of several target proteins.
Authors: Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov Journal: Nat Biotechnol Date: 2008-02-17 Impact factor: 54.908
Authors: Sang Y Ha; Jeeyun Lee; So Y Kang; In-Gu Do; Soomin Ahn; Joon O Park; Won K Kang; Min-Gew Choi; Tae S Sohn; Jae M Bae; Sung Kim; Minji Kim; Seonwoo Kim; Cheol K Park; Sai-Hong Ignatius Ou; Kyoung-Mee Kim Journal: Mod Pathol Date: 2013-06-28 Impact factor: 7.842
Authors: Jochen K Lennerz; Eunice L Kwak; Allison Ackerman; Michael Michael; Stephen B Fox; Kristin Bergethon; Gregory Y Lauwers; James G Christensen; Keith D Wilner; Daniel A Haber; Ravi Salgia; Yung-Jue Bang; Jeffrey W Clark; Benjamin J Solomon; A John Iafrate Journal: J Clin Oncol Date: 2011-10-31 Impact factor: 44.544
Authors: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Paul L Greer; Daniel M Bear; Jean-Marc Lassance; Maria Lissitsyna Bloom; Tatsuya Tsukahara; Stan L Pashkovski; Francis Kei Masuda; Alexandra C Nowlan; Rory Kirchner; Hopi E Hoekstra; Sandeep Robert Datta Journal: Cell Date: 2016-05-26 Impact factor: 41.582
Authors: Scott E Jordan; Heba Saad; Alex Sanchez Covarrubias; John Siemon; J Matt Pearson; Brian M Slomovitz; Marilyn Huang; Andre Pinto; Matthew Schlumbrecht; Sophia Hl George Journal: Gynecol Oncol Date: 2020-09-18 Impact factor: 5.482
Authors: Seung Tae Kim; Tae Jin Ahn; Eunjin Lee; In-Gu Do; Su Jin Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Suk Hyeong Kim; Jeeyun Lee; Hee Cheol Kim Journal: BMC Cancer Date: 2015-10-20 Impact factor: 4.430
Authors: Mi Hwa Heo; Hee Kyung Kim; Hansang Lee; Kyoung-Mee Kim; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Young Suk Park; Seung Tae Kim Journal: J Cancer Date: 2017-05-12 Impact factor: 4.207
Authors: Cristina Aguado; Cristina Teixido; Ruth Román; Roxana Reyes; Ana Giménez-Capitán; Elba Marin; Carlos Cabrera; Nuria Viñolas; Sergi Castillo; Silvia Muñoz; Ainara Arcocha; Laura López-Vilaró; Ivana Sullivan; Erika Aldeguer; Sonia Rodríguez; Irene Moya; Santiago Viteri; Andrés Felipe Cardona; Ramon Palmero; Cristina Sainz; Miguel Mesa-Guzmán; Maria D Lozano; Andrés Aguilar-Hernández; Alejandro Martínez-Bueno; María González-Cao; Elena Gonzalvo; William P J Leenders; Rafael Rosell; Luis M Montuenga; Aleix Prat; Miguel A Molina-Vila; Noemi Reguart Journal: Mol Oncol Date: 2020-12-07 Impact factor: 7.449